Chemotherapy for Patients with Intermediate- and Poor-Risk Germ-Cell Tumors

Two different types of cisplatin-based therapies produced similar, and unimpressive, outcomes in these patient groups.

Cisplatin-based combination chemotherapy yields cure rates >90% in patients with nonseminomatous germ-cell tumors that are classified by the International Germ Cell Cancer Collaborative Group (IGCCCG) as good risk. Unfortunately, patients with IGCCCG intermediate- and poor-risk tumors have cure rates of only 81% and 48%, respectively. These problematic subgroups of patients have been targeted for a variety of clinical approaches during the years, including cisplatin dose intensification, upfront ifosfamide therapy, and high-dose chemotherapy with stem-cell rescue. To date, none of these approaches has improved outcomes.

Members of the French Federation of Cancer Centers previously have conducted trials of a modified alternating chemotherapy …

Reviewing Author

Robert Dreicer, MD, MS, FACP

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, FACP

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports